Therapeutic Potential of Metabolites from Lactobacillus rhamnosus and Mare’s Milk in the Treatment of Dysbiosis.
Abstract: Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis. Agents modulating microbial dysbiosis caused by colitis can help in the remission of this disease. The current study describes the potential therapeutic effects of active metabolites from Lactobacillus rhamnosus and mare's milk which have potential therapeutic values on the intestinal microbiota and proinflammatory cytokines. The analysis of the V1-V3 16S rDNA site revealed significant changes in the intestinal microbiome composition before and after treatment in the treated group compared to the positive control group that was treated with 5-aminosalicylic acid (5-ASA). So the effect of the study product on dextran sulfate sodium-induced dysbiosis was shown to be more potent than the positive control, 5-ASA. The level of proinflammatory cytokines also decreased under the influence of a biological product.
Copyright © 2022 Samat Kozhakhmetov et al.
Publication Date: 2022-01-29 PubMed ID: 35132375PubMed Central: PMC8817857DOI: 10.1155/2022/3851478Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research investigates the therapeutic potential of metabolites present in Lactobacillus rhamnosus and mare’s milk to treat an inflammatory bowel condition known as Ulcerative colitis. The study results suggest that these metabolites can effectively alter the intestinal microbiota and reduce inflammatory responses, showing better outcomes than traditional treatment 5-aminosalicylic acid (5-ASA).
Introduction
- The paper begins by describing Ulcerative colitis, a type of inflammatory bowel disease. This disease causes ulcerations in the mucous membrane of the colon and rectum and is closely linked with the composition of gut microbiota.
- The crux of the research is to explore therapeutic methods that can help manage microbial dysbiosis caused by colitis and promote remission of the disease.
Focus of the Study
- The focus of the study was to examine the therapeutic effects of active metabolites from Lactobacillus rhamnosus and mare’s milk on intestinal microbiota and proinflammatory cytokines.
- These metabolites are believed to have potential therapeutic values which can aid in the treatment of dysbiosis induced by Ulcerative colitis.
Methodology and Results
- The researchers performed an analysis of the V1-V3 16S rDNA site to compare the composition of the intestinal microbiome before and after treatment.
- The result demonstrated significant changes in the microbiome composition in the group treated with the metabolites when compared to the positive control group that was treated with 5-aminosalicylic acid (5-ASA).
- Notably, the study product was found to impose a more potent effect in treating dextran sulfate sodium-induced dysbiosis than 5-ASA.
Impact of the Biological Product
- One of the noticeable effects is the decrease in the level of proinflammatory cytokines, which are substances secreted by certain cells of the immune system and have an effect on other cells.
- This result suggests that the biological product derived from Lactobacillus rhamnosus and mare’s milk could be a potential therapeutic agent in inhibiting inflammation response in ulcerative colitis patients.
Cite This Article
APA
Kozhakhmetov S, Babenko D, Kozhakhmetova S, Tuyakova A, Nurgaziyev M, Nurgozhina A, Muhanbetganov N, Chulenbayeva L, Sergazy S, Gulyayev A, Aljofan M, Kushugulova A.
(2022).
Therapeutic Potential of Metabolites from Lactobacillus rhamnosus and Mare’s Milk in the Treatment of Dysbiosis.
Biomed Res Int, 2022, 3851478.
https://doi.org/10.1155/2022/3851478 Publication
Researcher Affiliations
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- Kazakhstan Society of Researchers of Human Microbiome, Nur-Sultan, Kazakhstan.
- SaumalBioTech, Nur-Sultan, Kazakhstan.
- Innovation Center ArtScience, Nur-Sultan, Kazakhstan.
- Innovation Center ArtScience, Nur-Sultan, Kazakhstan.
- National Center for Biotechnology, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Nur-Sultan, Kazakhstan.
- Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Nur-Sultan, Kazakhstan.
- National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
- Kazakhstan Society of Researchers of Human Microbiome, Nur-Sultan, Kazakhstan.
MeSH Terms
- Animals
- Colitis, Ulcerative / drug therapy
- Colitis, Ulcerative / metabolism
- Colitis, Ulcerative / microbiology
- Cytokines / metabolism
- Dextran Sulfate
- Disease Models, Animal
- Dysbiosis / drug therapy
- Gastrointestinal Microbiome / drug effects
- Horses
- Lacticaseibacillus rhamnosus / metabolism
- Mesalamine / pharmacology
- Milk / metabolism
- Rats
- Rats, Wistar
Conflict of Interest Statement
The authors have no financial conflicts of interest to declare.
References
This article includes 24 references
- Bartolomaeus H, Balogh A, Yakoub M. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 2019;139:1407–1421.
- Dominguez-Bello M G, Godoy-Vitorino F, Knight R, Blaser M J. Role of the microbiome in human development. Gut 2019;68(6):1108–1114.
- Hold G L, Smith M, Grange C, Watt E R, El-Omar E M, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. World Journal of Gastroenterology 2014;20:1192–1210.
- Kaur N, Chen C-C, Luther J, Kao J Y. Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes 2011;2:211–216.
- Lakatos P L. Prediction of disease course in inflammatory bowel diseases. World Journal of Gastroenterology 2010;16:2589–2590.
- Shenderov B A. Metabiotics: novel idea or natural development of probiotic conception. Microbial Ecology in Health and Disease 2013;24.
- Monteagudo-Mera A, Rastall R A, Gibson G R, Charalampopoulos D, Chatzifragkou A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Applied Microbiology and Biotechnology 2019;103:6463–6472.
- Kushugulova A, Kozhakhmetov S, Supiyev A. Isolation and characterization of lactobacilli from traditional Kazakh dairy products. International Journal of Probiotics and Prebiotics 2013;8:95–99.
- Schulthess B, Bloemberg G V, Zbinden R, Bottger E C, Hombach M. Evaluation of the Bruker MALDI Biotyper for identification of Gram-positive rods: development of a diagnostic algorithm for the clinical laboratory. Journal of Clinical Microbiology 2014;52:1089–1097.
- Cervantes-Elizarrarás A, Cruz-Cansino D N, Ramírez-Moreno E. In vitro probiotic potential of lactic acid bacteria isolated from Aguamiel and Pulque and antibacterial activity against pathogens. Applied Sciences 2019;9(3):p. 601.
- Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 2018;34:i884–i890.
- McMurdie P J, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8(4, article e61217).
- Grimm M C, Elsbury S K, Pavli P, Doe W F. Interleukin 8: cells of origin in inflammatory bowel disease. Gut 1996;38:90–98.
- Sands B E, Kaplan G G. The role of TNFalpha in ulcerative colitis. Journal of Clinical Pharmacology 2007;47:930–941.
- Rather I A, Bajpai V K, Ching L L. Effect of a bioactive product SEL001 from Lactobacillus sakei probio65 on gut microbiota and its anti-colitis effects in a TNBS-induced colitis mouse model. Journal of Biological Sciences 2020;27(1):261–270.
- Liang Y-N, Yu J-G, Zhang D-B. Indigo naturalis ameliorates dextran sulfate sodium-induced colitis in mice by modulating the intestinal microbiota community. Molecules 2019;24:p. 4086.
- Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes 2012;3:544–555.
- Kozhakhmetov S, Babenko D, Kozhakhmetova S. Gut modulation of dysbiosis induced by dextran sulfate sodium. Food Bioscience 2021;42, article 101167.
- Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nature Reviews. Gastroenterology & Hepatology 2012;9:599–608.
- Bullock N R, Booth J C L, Gibson G R. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Current Issues in Intestinal Microbiology 2004;5(2):59–64.
- Zhou Y, Zhi F. Lower level of Bacteroides in the gut microbiota is associated with inflammatory bowel disease: a meta-analysis. BioMed Research International 2016;2016:9.
- Wang W, Xing W, Wei S. Semi-rational screening of probiotics from the fecal flora of healthy adults against DSS-induced colitis mice by enhancing anti-inflammatory activity and modulating the gut microbiota. Journal of Microbiology and Biotechnology 2019;29:1478–1487.
- Kozhakhmetov S, Babenko D, Nurgaziyev M. The combination of mare’s milk and grape polyphenol extract for treatment of dysbiosis induced by dextran sulfate sodium. Biodiversitas 2020;21(5):2275–2280.
- Kozhakhmetov S, Babenko D, Tuyakova A. Therapeutic potential of active metabolites from Lactobacillus rhamnosus and mare’s milk in the treatment of dysbiosis. Zenodo 2020.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
